BioProcess Technology Consultants Acquires CTD Quality Consulting, Launches New advanceONE™ Division
WOBURN, MASSACHUSETTS, October 20, 2014—BioProcess Technology Consultants, Inc. (BPTC), the leading strategic, technical, and regulatory consulting company for the global biopharmaceutical industry, announces the acquisition of CTD Quality Consulting, LLC.
CTD Quality Consulting, founded in 2004, specializes in regulatory submissions, regulatory strategy, GxP compliance training, and inspection readiness for pharmaceutical, biopharmaceutical, and medical device companies.
“BioProcess Technology Consultants is the ideal company to continue offering the highest level of quality and regulatory writing and training services that I have strived to build over the years. I wish them continued success in building this business and am pleased to continue as an advisor to them,” said Michelle H. Foster, Ph.D., Founder and Principal of CTD Quality Consulting.
With the acquisition of CTD Quality Consulting, BPTC also announces the formation of a new division, advanceONETM. The division consolidates the CMC quality, regulatory, and compliance services of both companies into a full suite of comprehensive high-value strategic and project-driven services for biopharmaceutical, small molecule, and medical device clients. According to Sheila Magil, Ph.D., Senior Consultant and quality expert at BPTC, “advanceONE™ will significantly expand the quality, regulatory, and compliance services we offer our clients throughout the entire product lifecycle.”
To further assist with the integration of CTD Quality and management of new advanceONE™ projects, BPTC is also pleased to announce the appointment of Alfred R. Doig, Jr., M.S., as Manager of advanceONE™. Mr. Doig has more than 30 years of business development and project management experience in the life sciences industry and previously directed the publishing and editorial activities at Drug & Market Development Reports and Insight Pharma Reports. He was also Contributing Editor at BioProcess Journal and has assisted BPTC with the continuing updates of the Company’s three-part guide on Good Manufacturing, Laboratory, and Clinical Practices. Mr. Doig holds M.S. degrees in Health Sciences and Biochemistry from Northeastern University and Biochemical Engineering from M.I.T.
“The capabilities of CTD Quality Consulting are synergistic to those of BPTC,” said Howard L. Levine, Ph.D., President and Founder of BPTC. “With this acquisition, and the formation of advanceONE™, we are now better positioned to provide our clients with a truly robust ‘one-stop-shop’ for all their global quality, regulatory, and compliance needs. I am also delighted to welcome Al Doig to the BPTC family. Many of us have had the pleasure of working with Al in the preparation and publication of our widely read reports and look forward to his valuable contributions to the Company and our clients.”
About BioProcess Technology Consultants
Founded in 1994, BPTC is the recognized worldwide leader in biologics Chemistry, Manufacturing, and Controls (CMC) consulting, providing a full range of technical, regulatory, and strategic assistance to pharmaceutical and biotechnology companies in the development and commercialization of biopharmaceutical products. The Company works with clients globally to find and apply solutions to the challenges of biopharmaceutical product development from clone to commercial®. BPTC helps develop manufacturing processes and strategies that enhance the overall value of client companies and accelerate the advancement of new products from clone to clinic®. BPTC also helps investors make informed decisions by providing technical and business evaluations of new products and technologies and product discovery, development, and commercialization plans of potential investments and existing portfolio companies. For more information about BPTC, visit http://www.bptc.com and follow the Company on Twitter at bptcGlobal or LinkedIn at http://www.linkedin.com/company/bioprocess-technology-consultants-inc.